Aug 162013
 

Animal_mitochondrion_diagram_en_(edit).svg

Scientists have discovered that an active ingredient in an over-the-counter skin cream slows or stops the effects of Parkinson’s disease on brain cells.

The active ingredient in an over-the-counter skin cream might do more than prevent wrinkles. Scientists have discovered that the drug, called kinetin, also slows or stops the effects of Parkinson’s disease on brain cells.

Scientists identified the link through biochemical and cellular studies, but the research team is now testing the drug in animal models of Parkinson’s. The research is published in the August 15, 2013 issue of the journal Cell.

“Kinetin is a great molecule to pursue because it’s already sold in drugstores as a topical anti-wrinkle cream,” says HHMI investigator Kevan Shokat of the University of California, San Francisco. “So it’s a drug we know has been in people and is safe.”

Parkinson’s disease is a degenerative disease that causes the death of neurons in the brain. Initially, the disease affects one’s movement and causes tremors, difficulty walking, and slurred speech. Later stages of the disease can cause dementia and broader health problems. In 2004, researchers studying an Italian family with a high prevalence of early-onset Parkinson’s disease discovered mutations in a protein called PINK1 associated with the inherited form of the disease.

Since then, studies have shown that PINK1 normally wedges into the membrane of damaged mitochondria inside cells that causes another protein, Parkin, to be recruited to the mitochondria, which are organelles responsible for energy generation. Neurons require high levels of energy production, therefore when mitochondrial damage occurs, it can lead to neuronal death. However, when Parkin is present on damaged mitochondria, studding the mitochondrial surface, the cell is able to survive the damage. In people who inherit mutations in PINK1, however, Parkin is never recruited to the organelles, leading to more frequent neuronal death than usual.

Shokat and his colleagues wanted to develop a way to turn on or crank up PINK1 activity, therefore preventing an excess of cell death, in those with inherited Parkinson’s disease. But turning on activity of a mutant enzyme is typically more difficult than blocking activity of an overactive version.

“When we started this project, we really thought that there would be no conceivable way to make something that directly turns on the enzyme,” says Shokat. “For any enzyme we know that causes a disease, we have ways to make inhibitors but no real ways to turn up activity.”

His team expected it would have to find a less direct way to mimic the activity of PINK1 and recruit Parkin. In the hopes of more fully understanding how PINK1 works, they began investigating how PINK1 binds to ATP, the energy molecule that normally turns it on. In one test, instead of adding ATP to the enzymes, they added different ATP analogues, versions of ATP with altered chemical groups that slightly change its shape. Scientists typically must engineer new versions of proteins to be able to accept these analogs, since they don’t fit into the typical ATP binding site. But to Shokat’s surprise, one of the analogs—kinetin triphosphate, or KTP—turned on the activity of not only normal PINK1, but also the mutated version, which doesn’t bind ATP.

“This drug does something that chemically we just never thought was possible,” says Shokat. “But it goes to show that if you find the right key for the right lock, you’ll be able to open the door.”

To test whether the binding of KTP to PINK1 led to the same consequences as the usual ATP binding, Shokat’s group measured the activity of PINK1 directly, as well as the downstream consequences of this activity, including the amount of Parkin recruited to the mitochondrial surface, and the levels of cell death. Adding the precursor of KTP, kinetin, to cells—both those with PINK1 mutations and those with normal physiology—amplified the activity of PINK1, increased the level of Parkin on damaged mitochondria, and decreased levels of neuron death, they found.

“What we have here is a case where the molecular target has been shown to be important to Parkinson’s in human genetic studies,” says Shokat. “And now we have a drug that specifically acts on this target and reverses the cellular causes of the disease.”

Read more . . .

 

The Latest on: Parkinson’s Disease
  • Neil Diamond Was Diagnosed with Parkinson's Disease. Here's What To Know About the Condition
    on January 23, 2018 at 9:39 am

    Scott Dudelson—Getty Images By Jamie Ducharme 10:51 AM EST TIME Health For more, visit TIME Health. After half a century on the stage, musician Neil Diamond announced on Monday that he’s retiring from touring due to a recent Parkinson’s disease ... […]

  • Neil Diamond to quit touring, citing Parkinson's
    on January 23, 2018 at 6:08 am

    The Rock and Roll Hall of Famer, 76, announced that he is retiring from touring, following a recent diagnosis of Parkinson's disease. […]

  • Neil Diamond retires after Parkinson's disease diagnosis
    on January 23, 2018 at 5:39 am

    Neil Diamond, a recording star for more than 50 years, says he is done with concert tours. The singer-songwriter revealed he's been diagnosed with Parkinson's disease. Vladimir Duthiers reports. […]

  • Neil Diamond retires from touring after Parkinson's disease diagnosis
    on January 23, 2018 at 5:10 am

    Days shy of his 77th birthday, the rock legend is canceling his tour dates in Australia and New Zealand for March. He was on his 50th anniversary tour. The Rock and Roll Hall of Famer offered his "sincerest apologies" to those who planned to go to his ... […]

  • Neil Diamond retires from touring after Parkinson's diagnosis
    on January 23, 2018 at 5:07 am

    Singer Neil Diamond has announced he will retire from touring, after a recent diagnosis of Parkinson's disease. Diamond, who turns 77 on Wednesday, cancelled his March tour dates for Australia and New Zealand on medical advice. The Solitary Man singer was ... […]

  • Neil Diamond, Rock and Roll Hall of Famer, has Parkinson's disease
    on January 23, 2018 at 5:04 am

    NEW YORK -- Neil Diamond is retiring from touring after he says he was diagnosed with Parkinson's disease. Days shy of his 77th birthday, the rock legend is canceling his tour dates in Australia and New Zealand for March. He was on his 50th anniversary tour. […]

  • Neil Diamond announces Parkinson’s diagnosis and retirement
    on January 23, 2018 at 1:14 am

    Grammy Award winning singer and songwriter Neil Diamond announced he has been diagnosed with Parkinson’s disease and is retiring from concert touring. Grammy Award winning singer and songwriter Neil Diamond announced he has been diagnosed with Parkinson ... […]

  • Neil Diamond diagnosed with Parkinson's, retires from touring
    on January 22, 2018 at 7:43 pm

    (CNN)Entertainer Neil Diamond has been diagnosed with Parkinson's disease, prompting the singer to retire from touring. "I have been so honored to bring my shows to the public for the past 50 years," Diamond said in a statement. "My sincerest apologies to ... […]

  • Neil Diamond announces Parkinson's diagnosis, immediate retirement
    on January 22, 2018 at 5:40 pm

    Neil Diamond has been diagnosed with Parkinson's disease, the singer revealed on his website Monday. The legendary musician will be retiring, and has canceled the third leg of this 50th Anniversary tour. “It is with great reluctance and disappointment ... […]

  • Neil Diamond Announces Retirement From Touring After Parkinson’s Disease Diagnosis
    on January 22, 2018 at 5:06 pm

    Grammy-winning singer-songwriter Neil Diamond today announced his retirement from touring due to his recent diagnosis of Parkinson’s disease. Based on his doctors’ advice, the third leg of Diamond’s 50th Anniversary tour, scheduled for Australia and ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: